20:40 , Jan 18, 2019 |  BC Week In Review  |  Financial News

Gore Range closes its inaugural fund

Gore Range Capital closed Fund I on Jan. 14. The firm declined to disclose how much Fund I raised. Fund I has made 13 investments, including in neuroscience and immuno-oncology company BioXcel Therapeutics Inc. (NASDAQ:BTAI)...
17:41 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Cell culture and mouse studies suggest inhibiting DPP-8 and DPP-9 could help treat AML. In 12 human AML cell lines, the DPP-8/DPP-9 inhibitor BXCL701 or two tool compound dual DPP-8/DPP-9...
23:21 , Jul 13, 2018 |  BioCentury  |  Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
16:46 , Mar 16, 2018 |  BC Week In Review  |  Financial News

AI play BioXcel raises $60M IPO

Artificial intelligence company BioXcel Therapeutics Inc. (NASDAQ:BTAI) raised $60 million on March 8 through the sale of 5.5 million shares at $11 in an upsized IPO underwritten by Barclays, UBS, BMO and Canaccord Genuity. The...
19:25 , Mar 8, 2018 |  BC Extra  |  Financial News

AI play BioXcel raises $60M IPO

BioXcel Therapeutics Inc. (NASDAQ:BTAI) gained $0.03 to $11.03 Thursday after the artificial intelligence company raised $60 million through the sale of 5.5 million shares at $11 in an upsized IPO underwritten by Barclays, UBS, BMO...
20:22 , Feb 23, 2018 |  BC Week In Review  |  Financial News

BioXcel Therapeutics proposes $69M IPO

Artificial intelligence company BioXcel Therapeutics Inc. (Branford, Conn.) proposed on Feb. 13 to raise up to $69 million in an IPO on NASDAQ underwritten by Barclays, UBS Securities, BMO Capital Markets and Canaccord Genuity. BioXcel...
19:09 , May 19, 2017 |  BC Week In Review  |  Company News

BioXcel creates subsidiary to develop cancer, neurology candidates

BioXcel Corp. (Branford, Conn.) launched new subsidiary BioXCel Therapeutics Inc. (BTI), which will use artificial intelligence-driven R&D to identify indications for candidates that demonstrated safety but not efficacy in Phase II testing or later. BTI's...